

CITATION REPORT

List of articles citing

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

DOI: 10.1016/s0149-2918(01)80132-6
Clinical Therapeutics, 2001, 23, 1603-14.

Source: <https://exaly.com/paper-pdf/32406189/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
399	Stevens-Johnson syndrome associated with abacavir therapy. 2002 , 35, 902		14
398	Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. 2002 , 288, 207-15		220
397	Colistin: an antimicrobial for the 21st century?. 2002 , 35, 901-2		70
396	Successful treatment of Enterococcus faecalis prosthetic valve endocarditis with linezolid. 2002 , 35, 902-4		35
395	Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1. 2002 , 34, 535-42		24
394	Tolerabilities of antiretrovirals in paediatric HIV infection. 2002 , 25, 973-91		12
393	Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. 2002 , 359, 727-32		1161
392	Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. 2002 , 359, 1121-2		692
391	Risk factor analysis of hypersensitivity reactions to abacavir. <i>Clinical Therapeutics</i> , 2002 , 24, 565-73	3.5	104
390	The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes. 2002 , 142, 135-54		102
389	Pharmacoepidemiology and drug safety. 2002 , 11, 255-70		
388	Antiretroviral Therapy-associated Serious and Life-threatening Toxicities. 2003 , 5, 429-438		2
387	Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial. <i>Pharmacotherapy</i> , 2003 , 23, 1432-40	5.8	1
386	TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. 2003 , 4, 79-86		70
385	Epidemiological risk factors for hypersensitivity reactions to abacavir. 2003 , 4, 321-4		44
384	Early versus delayed antiretroviral therapy in patients with HIV infection : a review of the current guidelines from an immunological perspective. 2003 , 63, 1325-37		11
383	Cutaneous manifestations of antiviral therapy. 2003 , 48, 985-6		4

382	Reasons for early abacavir discontinuation in HIV-infected patients. 2003 , 37, 1392-7	32
381	Current management challenges in HIV: tolerability of antiretrovirals and metabolic complications. 2003 , 17, 221-33	16
380	Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults. 2003 , 4, 231-43	6
379	Unusual clinical presentation of hypersensitivity reaction to abacavir. 2003 , 17, 2403-4	4
378	Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/abacavir regimen in underrepresented HIV-infected patients. 2003 , 34, 174-83	58
377	Monitoring of long-term toxicities of HIV treatments: an international perspective. 2003 , 17, 2407-17	27
376	Assessment of autonomic and cardiovascular function in HIV disease. 2003 , 40, 105-39	4
375	Pharmacogenetics to predict drug-related adverse events. 2004 , 32 Suppl 1, 9-12	15
374	Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. 2004 , 38, 2171-2	79
373	Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramune-zyrtec double-blind, placebo-controlled trial. 2004 , 38, e66-72	17
372	The pharmacogenetics of antiretroviral therapy: a review of studies to date. 2004 , 39, 98-106	30
371	Association of aspirin with eosinophilia in peripheral blood. 2004 , 38, 2172-3	4
370	Safety/Tolerability and Efficacy of Abacavir-Containing Combination Therapy in HIV-1-Infected Adults in a Clinical Practice Setting: Results of ZORRO. 2004 , 12, 15-25	1
369	Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. 2004 , 23, 625-30	76
368	Determination of abacavir in human plasma by high-performance liquid chromatography with ultraviolet detection and the analytical error function. 2004 , 18, 862-5	8
367	Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014). 2004 , 20, 1103-14	37
366	Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naïve HIV-infected adults. 2004 , 39, 1038-46	179
365	Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el VIH (octubre 2004). 2004 , 22, 564-642	1

364	Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. 2004 , 101, 4180-5	397
363	Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. 2004 , 5, 203-11	235
362	[Risk factors for Abacavir-induced hypersensitivity syndrome in the "real world"]. 2004 , 52, 529-33	9
361	Sweet's syndrome following abacavir therapy. 2004 , 51, 474-5	24
360	SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. 2004 , 18, 1529-37	149
359	Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. 2004 , 14, 335-42	236
358	The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. 2004 , 35, 22-32	127
357	Reply. 2004 , 14, 784	0
356	HLA-B*5701 and abacavir hypersensitivity. 2004 , 14, 783-4; author reply 784	6
355	Clinical and immunogenetic correlates of abacavir hypersensitivity. 2005 , 19, 979-81	149
354	Host determinants of antiretroviral drug activity. 2005 , 18, 543-9	13
353	Antiretroviral therapy: an update for the non-AIDS specialist. 2005 , 17, 479-84	14
352	Adverse Drug Reactions and Interactions: Mechanisms, Risk Factors, Detection, Management and Prevention. 2005 , 91-125	
351	Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients. 2005 , 18, 58-66	26
350	[An analysis fo causes for the discontinuation of a simplified antiretroviral regimen with abacavir, lamivudine and zidovudine]. 2005 , 29, 164-70	4
349	Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment. <i>BMC Infectious Diseases</i> , 2005 , 5, 2	4 36
348	A comprehensive listing of bioactivation pathways of organic functional groups. 2005 , 6, 161-225	526
347	Pharmacogenomics and drug development. 2005 , 6, 857-64	20

346	Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. 2005 , 4, 201-18	35
345	Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection. 2005 , 3, 871-83	8
344	Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. 2006 , 43, 99-102	263
343	Chapter 5 Idiosyncratic Drug Reactions: Clinical Evidence for Mechanistic Hypotheses. 2006 , 1, 139-183	
342	The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. 2006 , 368, 476-82	290
341	Abacavir/lamivudine combination in the treatment of HIV-1 infection: a review. 2006 , 7, 2571-80	4
340	Antiretroviral therapy: a primer for dermatologists. 2006 , 24, 537-47, vii	
339	Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy. 2006 , 29, 811-26	9
338	Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy. 2006 , 66, 1971-87	42
337	[Antiretroviral treatment associated life-threatening adverse events]. 2006 , 126, 744-9	7
336	Genetic factors in the predisposition to drug-induced hypersensitivity reactions. <i>AAPS Journal</i> , 2006 , 8, E20-6	3.7 66
335	[Not Available]. 2006 , 61, 171-6	0
334	Management of antiretroviral drug toxicity. 2006 , 1, 430-6	
333	Predictors for lower quality of life in the HAART era among HIV-infected men. 2006 , 42, 470-7	98
332	Current therapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome. 2006 , 84, 18-22	7
331	Pharmacogenetics in clinical practice: considerations for testing. 2006 , 6, 193-205	12
330	Host pharmacogenetics in the treatment of HIV and cancer. 2006 , 1, 107-16	2
329	Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again. 2006 , 7, 15-23	18

328	The clinical implications of antiretroviral pharmacogenomics. 2006 , 7, 587-96		16
327	Kaposi's sarcoma in HIV-infected patients: when and how should we evaluate bone involvement?. 2007 , 21, 2251-2		5
326	Use of pairwise marker combination and recursive partitioning in a pharmacogenetic genome-wide scan. <i>Pharmacogenomics Journal</i> , 2007 , 7, 180-9	3.5	10
325	Drug hypersensitivity reactions in patients with HIV disease. 2007 , 3, 395-410		5
324	Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary. 2007 , 196 Suppl 3, S449-56		47
323	HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. 2007 , 59, 591-3		52
322	Pharmacogenetic Considerations in the Management of HIV Infection. 2007 , 20, 234-245		1
321	Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. 2007 , 60, 599-604		67
320	A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase. 2007 , 44, 1503-8		31
319	Abacavir/lamivudine fixed-dose combination tablet for the treatment of HIV-1 infection. 2007 , 2, 11-21		2
318	Fixed-dose combination of abacavir, lamivudine and zidovudine for HIV therapy. 2007 , 2, 23-30		1
317	HLA-B*5701 clinical testing: early experience in the United States. <i>Pharmacogenetics and Genomics</i> , 2007 , 17, 857-60	1.9	18
316	Acute fibrinous and organizing pneumonia as a rare presentation of abacavir hypersensitivity reaction. 2007 , 21, 2116-7		30
315	Drug hypersensitivity in HIV. 2007 , 7, 324-30		72
314	A truvada hypersensitivity reaction simulating abacavir hypersensitivity. 2007 , 21, 2252-3		1
313	Lack of anti-HIV activity of entecavir in an HIV patient coinfecting with hepatitis B and delta viruses. 2007 , 21, 2253-4		4
312	Adverse cutaneous reactions to antimicrobials in patients with human immunodeficiency virus infection. 2007 , 18, 8-25		2
311	Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. 2007 , 21, 1233-44		40

310	Large lymphadenopathies complicating the abacavir hypersensitivity reaction. 2007 , 21, 2254-6	4
309	[Incidence and reasons of premature discontinuation of abacavir: results of a hospital investigation among 628 patients]. 2007 , 37, 684-7	
308	[Hypersensitivity reactions to antiretroviral agents in HIV-infected patients]. 2007 , 128, 61-9	1
307	Nucleoside and nucleotide reverse transcriptase inhibitors in children. 2007 , 27, 509-31	6
306	Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update. 2007 , 7, 333-42	47
305	HLA-B*5701 typing: evaluation of an allele-specific polymerase chain reaction melting assay. 2007 , 70, 58-61	40
304	PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events. 2008 , 7, 121-9	35
303	Pharmacogenetics in drug discovery and development: a translational perspective. 2008 , 7, 807-17	99
302	A review of the pharmacokinetics of abacavir. 2008 , 47, 351-71	94
301	Diagnosis and management of HIV drug hypersensitivity. 2008 , 121, 826-832.e5	48
300	HLA-B*5701 screening for hypersensitivity to abacavir. 2008 , 358, 568-79	1364
299	Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. 2008 , 28, 822-32	268
298	[HLA-B*5701 and hypersensitivity reactions to abacavir. Study methods and clinical relevance]. 2008 , 26 Suppl 6, 34-9	
297	[Prospective validation of a pharmacogenetic test: the PREDICT-1 study]. 2008 , 26 Suppl 6, 40-4	1
296	Toxicodermias en pacientes con síndrome de inmunodeficiencia adquirida. 2008 , 23, 303-308	
295	Abacavir hypersensitivity reaction: an update. 2008 , 42, 387-96	60
294	Fatal disseminated toxoplasmosis with congenital transmission in an African migrant. 2008 , 22, 1523-5	
293	Pulmonary arterial hypertension and HIV infection: authors' reply. 2008 , 22, 2220	

292	Pharmacogenetic determinants of immediate and delayed reactions of drug hypersensitivity. 2008 , 14, 2770-7		37
291	Pharmacogenetic information derived from analysis of HLA alleles. 2008 , 9, 207-14		31
290	Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. <i>Pharmacogenomics Journal</i> , 2008 , 8, 365-74	3-5	77
289	Abacavir hypersensitivity. 2008 , 358, 2514-5; author reply 2515-6		8
288	Current trends in screening across ethnicities for hypersensitivity to abacavir. 2008 , 9, 1531-41		9
287	HIV pharmacogenetics in clinical practice: recent achievements and future challenges. 2008 , 6, 544-54		10
286	The safety of antiretroviral drugs. 2008 , 7, 1-4		9
285	An unusual abacavir reaction. 2008 , 22, 1520-2		9
284	Severe abacavir hypersensitivity reaction in a patient tested HLA-B*5701 negative. 2008 , 22, 1522-3		18
283	HLA-B*5701 screening for hypersensitivity to abacavir. 2008 , 5, 297-300		1
282	Pulmonary arterial hypertension and HIV infection. 2008 , 22, 2219-20; author reply 2220		8
281	The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. 2008 , 22, 2025-33		120
280	A study of rectal mucosa administration of IL-2 in treatment of HIV/AIDS: a novel method for the treatment of HIV/AIDS. 2008 , 22, 2222-4		
279	Abacavir-induced febrile agranulocytosis and anaemia. 2008 , 22, 2221-2		2
278	Significant differences in DNA viral load between HIV-1 and HIV-2 infected patients. 2008 , 22, 1519-20		1
277	Abacavir-induced reaction with fever and severe skin rash in a patient tested human leukocyte antigen-B*5701 negative. 2009 , 20, 276-7		12
276	A study of HIV provider attitudes toward HLA-B 5701 testing in the United States. 2009 , 23, 957-63		3
275	TNF, LTA, HSPA1L and HLA-DR gene polymorphisms in HIV-positive patients with hypersensitivity to cotrimoxazole. 2009 , 10, 531-40		27

274	Prevalence of HLA-B*5701 in HIV-Infected Patients in Spain (Results of the EPI Study). 2009 , 10, 48-51	9
273	Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example. 2009 , 10, 225-33	35
272	The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety. 2009 , 34, 6-17	35
271	Abacavir/lamivudine fixed dose combination in the treatment of patients with HIV infection. 2009 , 3, 19-29	1
270	Correlaci3n, en pacientes infectados por el VIH-1 y previamente tratados, entre la reacci3n de hipersensibilidad a abacavir y el alelo HLA-B*5701. 2009 , 33, 155-160	3
269	Update in HIV Medicine for the Generalist. 2009 , 24, 276-282	78
268	HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. 2009 , 41, 816-9	818
267	Changes in biomarkers of cardiovascular risk after a switch to abacavir in HIV-1-infected individuals receiving combination antiretroviral therapy. 2009 , 10, 627-33	27
266	Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele. 2009 , 33, 155-160	
265	Successful translation of pharmacogenetics into the clinic: the abacavir example. <i>Molecular Diagnosis and Therapy</i> , 2009 , 13, 1-9	4.5 86
264	HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects. 2009 , 46, 153-65	25
263	Genetic detection of HLA-B*5701 allele for prediction of Abacavir hypersensitivity among HIV-positive patients in Polish population. 2009 , 8, 13-16	1
262	Personalizing antiretroviral therapy: is it a reality?. 2009 , 6, 393-408	5
261	A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. 2009 , 51, 290-7	62
260	Pipeline pharmacogenetics: a novel approach to integrating pharmaco-genetics into drug development. 2009 , 15, 3754-63	7
259	An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe. <i>Pharmacogenetics and Genomics</i> , 2010 , 20, 307-14	1.9 29
258	Abacavir-induced agranulocytosis in two Taiwanese patients tested HLA-B*5701-negative. 2010 , 24, 1238-9	2
257	Safe co-administration of raltegravir, pegylated-interferon and, ribavirin in HIV individuals with hepatitis C virus-related liver damage. 2010 , 24, 1231-3	6

256	Personalized medicine for HLA-associated drug-hypersensitivity reactions. 2010 , 7, 495-516	15
255	Pharmacogenetics and the pharmaceutical industry. 2010 , 16, 238-44	7
254	Increasing HIV infectivity by Neisseria gonorrhoea: role of host antiapoptotic proteins in enhanced transmission. 2010 , 24, 1237	2
253	Universal antiretroviral therapy among pregnant and postpartum HIV-infected women would improve maternal health and decrease postnatal HIV transmission. 2010 , 24, 1239-41	5
252	Clinical Approach to HIV-Associated Pulmonary Disease. 2010 , 17, 210-217	
251	Testing but not treating: missed opportunities and lost lives in the South African antiretroviral therapy programme. 2010 , 24, 1233-5	22
250	Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany. 2010 , 15, 145-51	15
249	Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. 2010 , 66, 755-74	48
248	Absence of mitochondrial toxicity in hearts of transgenic mice treated with abacavir. 2010 , 10, 146-51	4
247	Pharmacogenetics of antiretrovirals. 2010 , 85, 190-200	76
246	High rate of loss to clinical follow up among African HIV-infected patients attending a London clinic: a retrospective analysis of a clinical cohort. 2010 , 13, 29	29
245	Introduction of pharmacogenetic screening for the human leucocyte antigen (HLA) B*5701 variant in Polish HIV-infected patients. 2010 , 11, 345-8	10
244	Successful implementation of a national HLA-B*5701 genetic testing service in Canada. 2010 , 75, 12-8	25
243	Abacavir/lamivudine combination in the treatment of HIV: a review. 2010 , 6, 83-94	7
242	[Could idiosyncratic thinking fit with >?]. 2010 , 26, 641-6	
241	Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. 2010 , 51, 963-72	327
240	Pharmacogenetics of drug hypersensitivity. 2010 , 11, 973-87	90
239	Prediction of severe adverse drug reactions using pharmacogenetic biomarkers. 2010 , 25, 122-33	21

238	Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naïve, HIV-1-infected adults: 48-week results from the ASSERT study. 2010 , 55, 49-57	185
237	Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants. 2011 , 253-64	13
236	Cerebrospinal fluid HIV-1 virological escape with lymphocytic meningitis under lopinavir/ritonavir monotherapy. 2010 , 24, 1235-6	5
235	Visceral involvements and long-term sequelae in drug-induced hypersensitivity syndrome. 2010 , 94, 743-59, xi	78
234	Pharmacogenetics and Pharmacogenomics. 2010 , 325-345	
233	Drug allergy. 2010 , 125, S126-37	160
232	Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain. 2010 , 28, 590-5	22
231	[AIDS Study Group/Spanish AIDS Plan consensus document on antiretroviral therapy in adults with human immunodeficiency virus infection (updated January 2010)]. 2010 , 28, 362.e1-91	10
230	[HLA-B*5701 and abacavir hypersensitivity reaction]. 2010 , 58, e95-100	
229	Pharmacogenetics and human genetic polymorphisms. 2010 , 429, 435-49	78
228	Pharmacogenetics. 2010 , 635-647	
227	Pharmacogenetics of idiosyncratic adverse drug reactions. 2010 , 477-91	26
226	Adverse Drug Reactions. 2010 ,	4
225	Impact of antiretroviral therapy on growth, body composition and metabolism in pediatric HIV patients. 2010 , 12, 187-99	23
224	Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. 2010 , 28, 1025-39	38
223	The changing epidemiology of HIV-infected patients in the intensive care unit. 2011 , 26, 151-64	32
222	Pharmacogenomic Testing in Current Clinical Practice. 2011 ,	1
221	Reactive aldehyde metabolites from the anti-HIV drug abacavir: amino acid adducts as possible factors in abacavir toxicity. 2011 , 24, 2129-41	26

220	[Management of antiretroviral drug toxicity]. 2011 , 29, 535-44	5
219	[National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)]. 2011 , 29, 209.e1-103	23
218	Association of the genetic marker for abacavir hypersensitivity HLA-B*5701 with HCP5 rs2395029 in Mexican Mestizos. 2011 , 12, 809-14	33
217	Approach to pruritus in the adult HIV-positive patient. 2011 , 30, 101-6	15
216	Critical appraisal and update on tenofovir in management of human immunodeficiency virus infection. 2011 , 55	2
215	SEVERE, ACUTE ALLERGIC AND IMMUNOLOGICAL REACTIONS II: OTHER HYPERSENSITIVITIES AND IMMUNE DEFECTS, INCLUDING HIV. 184-193	
214	Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity. 2011 , 78, 11-20	38
213	Hypersensitivity reactions to HIV therapy. 2011 , 71, 659-71	56
212	Pharmacogenetics of cutaneous adverse drug reactions. 2011 , 38, 246-54	78
211	Critical illness in HIV-infected patients in the era of combination antiretroviral therapy. 2011 , 8, 301-7	22
210	The toxicogenetics of antiretroviral therapy: the evil inside. 2011 , 18, 209-19	6
209	Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy. 2011 , 58, 38-46	13
208	Abacavir and lamivudine for the treatment of human immunodeficiency virus. 2011 , 12, 2129-38	3
207	Genomics and drug response. 2011 , 364, 1144-53	455
206	Are predictive biomarkers of toxicity worth having? An economic model. 2012 , 42, 4-10	2
205	Pharmacogenetics and dermatology. 2012 , 1-14	
204	Liver toxicity of antiretroviral drugs. 2012 , 32, 167-76	45
203	HLA-dependent hypersensitivity reaction to nevirapine in Chinese Han HIV-infected patients. <i>AIDS Research and Human Retroviruses</i> , 2012 , 28, 540-3	1.6 44

202	Regulatory Perspectives on Biomarker Development. 2012 , 229-254		
201	Pharmacology: A false sense of non-self. 2012 , 486, 479-81		4
200	HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury. 2012 , 2012, 760706		23
199	Bioactivation II: Phase I (Non-P450). 2012 , 1		
198	Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues. 2012 , 1,		33
197	The Pharmacogenomic HLA Biomarker Associated to Adverse Abacavir Reactions: Comparative Analysis of Different Genotyping Methods. 2012 , 13, 314-20		27
196	Pharmacogenetic screening for drug therapy: from single gene markers to decision making in the next generation sequencing era. 2012 , 44, 166-80		17
195	A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study. <i>AIDS Research and Human Retroviruses</i> , 2012 , 28, 1196-206	1.6	40
194	Translational research in infectious disease: current paradigms and challenges ahead. 2012 , 159, 430-53		34
193	Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. 2012 , 13, 1501-22		22
192	Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. <i>Clinical Pharmacology and Therapeutics</i> , 2012 , 91, 734-8	6.1	142
191	[Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)]. 2012 , 30, e1-89		16
190	Pharmacogenetics of Adverse Drug Reactions. 2012 , 295-321		1
189	Pharmacogenomic strategies in drug safety. 2012 , 9, e67-e74		4
188	Personalized medicine: changing the paradigm of drug development. 2012 , 823, 367-78		4
187	Genomics Applications for the Developing World. <i>Advances in Microbial Ecology</i> , 2012 ,		6
186	Copy number variation and incomplete linkage disequilibrium interfere with the HCP5 genotyping assay for abacavir hypersensitivity. 2012 , 16, 1111-4		15
185	. 2012 ,		5

184	Detection of abacavir hypersensitivity by ELISpot method. 2012 , 11, 227-34	12
183	2-Azabicyclo[2.2.1]hept-5-en-3-one: chemical profile of a versatile synthetic building block and its impact on the development of therapeutics. 2012 , 112, 4642-86	95
182	Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. 2012 , 52, 401-31	130
181	HLA alleles and drug hypersensitivity reactions. 2012 , 39, 99-105	26
180	Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status?. 2012 , 42, 411-6	37
179	Human leukocyte antigen-associated drug hypersensitivity. 2013 , 25, 81-9	65
178	Farmakogenetyka w praktyce klinicznej zakażenia HIV. 2013 , 12, 128-130	1
177	Abacavir (Ziagen(®)) use between 2003 and 2008 in France according to the electronic medical record NADIS(®). 2013 , 43, 467-74	1
176	[Consensus Statement by GeSIDA/National AIDS Plan Secretariat on antiretroviral treatment in adults infected by the human immunodeficiency virus (Updated January 2013)]. 2013 , 31, 602.e1-602.e98	7
175	Status report from 'double agent HLA': health and disease. 2013 , 55, 2-7	11
174	Management of persons infected with human immunodeficiency virus requiring admission to the intensive care unit. 2013 , 29, 603-20	6
173	Hypersensibilité médicamenteuse à l'abacavir. 2013 , 28, 120-124	
172	Highly efficient inhibition of human immunodeficiency virus type 1 reverse transcriptase by aptamers functionalized gold nanoparticles. 2013 , 5, 2756-64	42
171	T-cells from HLA-B*57:01+ human subjects are activated with abacavir through two independent pathways and induce cell death by multiple mechanisms. 2013 , 26, 759-66	40
170	Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine. 2013 , 56, 119-24	22
169	Critical care of persons infected with the human immunodeficiency virus. 2013 , 34, 307-23	7
168	Randomized placebo-controlled study of the safety, tolerability, antiviral activity, and pharmacokinetics of 10-day monotherapy with BMS-986001, a novel HIV NRTI, in treatment-experienced HIV-1-infected subjects. 2013 , 63, 346-54	11
167	Predictive ability of direct-to-consumer pharmacogenetic testing: when is lack of evidence really lack of evidence?. 2013 , 14, 341-4	10

166	Pharmacogenetic testing: Current Evidence of Clinical Utility. 2013 , 4, 155-169		25
165	Abacavir pharmacogenetics--from initial reports to standard of care. <i>Pharmacotherapy</i> , 2013 , 33, 765-75	5,8	32
164	Severe recurrent rhabdomyolysis-induced acute kidney injury in a HIV-infected patient on antiretroviral therapy. 2013 , 35, 1186-90		8
163	Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial. 2013 , 52, 735-44		12
162	Cardiac biomarkers in HIV-exposed uninfected children. 2013 , 27, 1099-108		17
161	96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study. <i>Antiviral Therapy</i> , 2013 , 18, 905-13	1.6	52
160	Severe Cutaneous Adverse Reactions. 2013 ,		
159	HIV Pharmacogenetics and Pharmacogenomics. 2013 , 1211-1229		
158	HLA and TCR Recognition of Medications in Severe Cutaneous Adverse Reactions. 2014 , 10, 51-61		3
157	Reactivation of hepatitis B virus infection associated with maraviroc use in an HIV-infected patient. 2014 , 28, 1079-80		1
156	Bioactivation of drugs in the skin: relationship to cutaneous adverse drug reactions. 2014 , 46, 1-18		26
155	Drug-reaction eosinophilia and systemic symptoms and drug-induced hypersensitivity syndrome. 2014 , 55, 15-23		30
154	Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review. 2014 , 15, 963-76		22
153	Adverse Drug Reactions. 2014 , 405-435		3
152	Drug reaction with eosinophilia and systemic symptoms associated with raltegravir use: case report and review of the literature. 2014 , 28, 1077-9		11
151	Massive hypereosinophilia and vasculitis associated with major expansion of interleukin-5-producing CD8+ T cells in HIV-1 infection. 2014 , 28, 1075-7		1
150	HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review. 2014 , 2014, 565320		45
149	T Lymphocytes as Tools in Diagnostics and Immunotoxicology. <i>Exs</i> , 2014 ,		1

148	Antiretroviral therapy: current drugs. 2014 , 28, 371-402		110
147	The frequency of HLA-B(*)57:01 and the risk of abacavir hypersensitivity reactions in the majority population of Costa Rica. 2014 , 75, 1092-6		10
146	Abacavir forms novel cross-linking abacavir protein adducts in patients. 2014 , 27, 524-35		19
145	Towards depersonalized abacavir therapy: chemical modification eliminates HLA-B*57 : 01-restricted CD8+ T-cell activation. 2015 , 29, 2385-95		14
144	Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion test Assessment Tool (CAT). 2015 , 21, 700-12		4
143	Comparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 care. <i>PLoS ONE</i> , 2015 , 10, e0123525	3.7	9
142	Abacavir-induced fulminant hepatic failure in a HIV/HCV co-infected patient. <i>BMJ Case Reports</i> , 2015 , 2015,	0.9	4
141	HLA-alleleotype associations with nevirapine-induced hypersensitivity reactions and hepatotoxicity: a systematic review of the literature and meta-analysis. <i>Pharmacogenetics and Genomics</i> , 2015 , 25, 186-98 ⁹	1.9	22
140	Adult HIV Infection Treatment Update 2014: An Approach to HIV Infection Management and Antiretroviral Treatment. 2015 , 11, 95-102		1
139	Individualized Medicine. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2015 ,	0.4	7
138	Prevalence of HLA-B*57:01 allele in Argentinean HIV-1 infected patients. 2015 , 86, 28-31		6
137	Role of dermatology in pharmacogenomics: drug-induced skin injury. 2015 , 16, 401-12		9
136	Pharmacogenetic Markers of Drug Efficacy and Toxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2015 , 98, 61-70	6.1	26
135	Clinical application of pharmacogenetics: focusing on practical issues. 2015 , 16, 1733-41		12
134	Adversomics: a new paradigm for vaccine safety and design. 2015 , 14, 935-47		33
133	The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future. 2015 , 79, 182-94		50
132	Direct PCR: a new pharmacogenetic approach for the inexpensive testing of HLA-B*57:01. <i>Pharmacogenomics Journal</i> , 2015 , 15, 196-200	3.5	18
131	Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review. 2015 , 48, 165-75		52

130	Myocarditis and Cardiomyopathy. 2016 , 27-58		1
129	Genetic Markers of the Host in Persons Living with HTLV-1, HIV and HCV Infections. 2016 , 8,		12
128	The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity. 2016 , 17,		56
127	MinION: A Novel Tool for Predicting Drug Hypersensitivity?. <i>Frontiers in Pharmacology</i> , 2016 , 7, 156	5.6	5
126	Validation of a rapid test for HLA-B*58:01/57:01 allele screening to detect individuals at risk for drug-induced hypersensitivity. 2016 , 17, 473-80		8
125	Validation of two commercial real-time PCR assays for rapid screening of the HLA-B*57:01 allele in the HIV clinical laboratory. 2016 , 237, 18-24		1
124	HLA and Delayed Drug-Induced Hypersensitivity. 2016 , 170, 163-79		25
123	Clinical and regulatory considerations in pharmacogenetic testing. 2016 , 73, 1999-2006		4
122	HLA-B*57: 01 genotyping in the prevention of hypersensitivity to abacavir: 5 years of experience. <i>Pharmacogenetics and Genomics</i> , 2016 , 26, 390-6	1.9	10
121	Cytochrome P450 and Non-Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics. 2016 , 44, 1229-45		70
120	Advances in the Pharmacogenomics of Adverse Drug Reactions. 2016 , 39, 15-27		21
119	Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial. 2016 , 3, e13-22		8
118	Pharmacogenetics of hypersensitivity drug reactions. 2017 , 72, 231-243		6
117	Leveraging Genomic Factors to Improve Benefit-Risk. 2017 , 10, 78-83		3
116	Prevalence of abacavir-associated hypersensitivity syndrome and HLA-B*5701 allele in a Portuguese HIV-positive population. 2017 , 2, 59-62		4
115	Rapid and Reliable Genotyping of HLA-B*57:01 in Four Chinese Populations Using a Single-Tube Duplex Real-Time Polymerase Chain Reaction Assay. <i>AIDS Research and Human Retroviruses</i> , 2017 , 33, 711-717	1.6	3
114	Rapid detection of HLA-B*5701 allele by in-house developed tetra-primer amplification refractory mutation system PCR. 2017 , 12, 150-153		1
113	First case of DRESS syndrome attributed to a spider bite. 2017 , 5, 1135-1136		2

112	The prevalence of human leukocyte antigen-B*57:01 allele in HIV-1-infected Moroccan subjects. 2017 , 9, 108-110			1
111	HLA-associated drug hypersensitivity and the prediction of adverse drug reactions. 2017 , 18, 1441-1457			20
110	Towards a personalized assessment of pancreatic function in diabetes. 2017 , 2, 275-285			
109	Brief Report: Should Abacavir Be a First-Line Alternative for Adults With HIV in Sub-Saharan Africa?. 2017 , 76, 188-192			1
108	The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions. 2017 , 69, 617-630			44
107	Dermatologic Manifestations of HIV Infection/AIDS. 2017 , 879-887.e1			1
106	Pharmacogenomics in Clinical Care and Drug Discovery. 2017 , 281-303			
105	HLA Association with Drug-Induced Adverse Reactions. 2017 , 2017, 3186328			55
104	Safety and Efficacy of Ziagen (Abacavir Sulfate) in HIV-Infected Korean Patients. <i>Infection and Chemotherapy</i> , 2017 , 49, 205-212	3.9		5
103	Management of Antiretrovirals in Critically Ill Patients: Great Progress But Potential Pitfalls. 2018 , 46, 663-665			1
102	Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort. 2018 , 19, 252-260			1
101	Biotechnology for Biomarkers. 2018 , 533-557			0
100	Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. 2018 , 118, 1599-1663			51
99	Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention. <i>Molecular Diagnosis and Therapy</i> , 2018 , 22, 297-314	4.5		8
98	HLAs: Key regulators of T-cell-mediated drug hypersensitivity. <i>Hla</i> , 2018 , 91, 3-16	1.9		46
97	Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments. <i>AAPS Journal</i> , 2017 , 20, 4	3.7		78
96	Drug Allergy and Adverse Drug Reactions. 2018 , 1-14			
95	Rapid Detection of HLA-B*57:01-Expressing Cells Using a Label-Free Interdigitated Electrode Biosensor Platform for Prevention of Abacavir Hypersensitivity in HIV Treatment. <i>Sensors</i> , 2019 , 19,	3.8		2

94	The Role of Conformational Dynamics in Abacavir-Induced Hypersensitivity Syndrome. <i>Scientific Reports</i> , 2019 , 9, 10523	4.9	4
93	Exhaustive Repertoire of Druggable Cavities at Protein-Protein Interfaces of Known Three-Dimensional Structure. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 9732-9742	8.3	8
92	Safety and Effectiveness Analysis of Kivexa® (lamivudine/abacavir sulfate) in Human Immunodeficiency Virus Infected Korean Patients. <i>Infection and Chemotherapy</i> , 2019 , 51, 150-160	3.9	2
91	HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia. <i>BMC Infectious Diseases</i> , 2019 , 19, 793	4	4
90	Low frequency of hypersensitivity reactions to abacavir in HIV infected patients in a referral center in Bahia, Brazil. <i>Brazilian Journal of Infectious Diseases</i> , 2019 , 23, 268-270	2.8	1
89	Pharmacogenomic Considerations in the Treatment of HIV Infection. 2019 , 227-245		
88	HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA observational database: a cohort study. <i>AIDS Research and Therapy</i> , 2019 , 16, 1	3	27
87	Pharmacogenomics as a Tool for Management of Drug Hypersensitivity Reactions. <i>Current Treatment Options in Allergy</i> , 2019 , 6, 1-17	1	1
86	HLA-B13:01 as a Risk Allele for Antiepileptic Drugs-Induced Cutaneous Adverse Reactions: Higher Risk for Cross-Reactivity?. <i>Frontiers in Neurology</i> , 2019 , 10, 614	4.1	2
85	Drug Allergy and Adverse Drug Reactions. 2019 , 491-504		
84	DNA polymerase- β hypothesis in nucleoside reverse transcriptase-induced mitochondrial toxicity revisited: A potentially protective role for citrus fruit-derived naringenin?. <i>European Journal of Pharmacology</i> , 2019 , 852, 159-166	5.3	2
83	Biomarkers of drug-induced liver injury. <i>Advances in Pharmacology</i> , 2019 , 85, 221-239	5.7	14
82	Recent developments in genetic/genomic medicine. <i>Clinical Science</i> , 2019 , 133, 697-708	6.5	42
81	HIV pharmacogenetics and pharmacogenomics: From bench to bedside. 2019 , 185-222		
80	Two cases of occupational allergic contact dermatitis caused by abacavir. <i>Contact Dermatitis</i> , 2019 , 80, 187-188	2.7	5
79	Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure. <i>Pharmacotherapy</i> , 2019 , 39, 40-54	5.8	12
78	Modification of the cyclopropyl moiety of abacavir provides insight into the structure activity relationship between HLA-B*57:01 binding and T-cell activation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020 , 75, 636-647	9.3	12
77	CD39 regulatory T cells modulate the immune response to carbamazepine in HLA-B*15:02 carriers. <i>Immunobiology</i> , 2020 , 225, 151868	3.4	5

76	Comparison of abacavir-specific effector and proliferating functions of CD8 T cells in abacavir-treated HIV-1 patients. <i>Microbiology and Immunology</i> , 2020 , 64, 210-218	2.7	1
75	Genetic variants associated with T cell-mediated cutaneous adverse drug reactions: A PRISMA-compliant systematic review-An EAACI position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020 , 75, 1069-1098	9.3	11
74	Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines. <i>Frontiers in Pharmacology</i> , 2020 , 11, 567048	5.6	12
73	Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions. <i>Frontiers in Pharmacology</i> , 2020 , 11, 969	5.6	17
72	Abacavir adverse reactions related with HLA-B*57: 01 haplotype in a large cohort of patients infected with HIV. <i>Pharmacogenetics and Genomics</i> , 2020 , 30, 167-174	1.9	2
71	Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 14357-14381	8.3	11
70	Pharmacogenomics in Precision Medicine. 2020 ,		
69	SWEDEGENE-a Swedish nation-wide DNA sample collection for pharmacogenomic studies of serious adverse drug reactions. <i>Pharmacogenomics Journal</i> , 2020 , 20, 579-585	3.5	5
68	Global Frequencies of Clinically Important HLA Alleles and Their Implications For the Cost-Effectiveness of Preemptive Pharmacogenetic Testing. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 160-174	6.1	16
67	Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters. 2021 ,		0
66	Genetic Variants Associated With Drug-Induced Hypersensitivity Reactions: towards Precision Medicine?. <i>Current Treatment Options in Allergy</i> , 2021 , 8, 42-59	1	
65	Pharmacogenetics and personalized medicine. 2021 , 193-219		
64	Prevalence of human leukocyte antigen HLA-B*57:01 in individuals with HIV in West and Central Africa. <i>BMC Immunology</i> , 2021 , 22, 48	3.7	0
63	The Role of Mitochondrial DNA Variation in Drug Response: A Systematic Review. <i>Frontiers in Genetics</i> , 2021 , 12, 698825	4.5	0
62	Improving turnaround times for HLA-B*27 and HLA-B*57:01 gene testing: a Barts Health NHS Trust quality improvement project. <i>BMJ Open Quality</i> , 2021 , 10,	1.9	0
61	T cell responses to drugs and drug metabolites. <i>Exs</i> , 2014 , 104, 137-63		4
60	HIV Co-Infection Drug Toxicity. 2012 , 683-699		1
59	Antiretroviral-therapy-associated lipodystrophy: current status and future directions. <i>Sexual Health</i> , 2005 , 2, 153-63	2	37

58	HCP5 rs2395029 is a rapid and inexpensive alternative to HLA-B*57:01 genotyping to predict abacavir hypersensitivity reaction in Spain. <i>Pharmacogenetics and Genomics</i> , 2021 , 31, 53-59	1.9	2
57	Prevalence of human leukocyte antigen-B*5701 among HIV-infected children in Thailand and Cambodia: implications for abacavir use. <i>Pediatric Infectious Disease Journal</i> , 2013 , 32, 252-3	3.4	12
56	The PAGE Study: How Genetic Diversity Improves Our Understanding of the Architecture of Complex Traits.		14
55	Severe myositis on commencement of efavirenz, abacavir and lamivudine, in the absence of lactic acidosis or classical abacavir hypersensitivity. <i>BMJ Case Reports</i> , 2009 , 2009,	0.9	4
54	A transgenic mouse model for HLA-B*57:01-linked abacavir drug tolerance and reactivity. <i>Journal of Clinical Investigation</i> , 2018 , 128, 2819-2832	15.9	31
53	HLA-B*5701 testing to predict abacavir hypersensitivity. <i>PLOS Currents</i> , 2010 , 2, RRN1203		34
52	Relaxation effect of abacavir on rat basilar arteries. <i>PLoS ONE</i> , 2015 , 10, e0123043	3.7	3
51	Frequency of HLA B*5701 allele carriers in abacavir treated-HIV infected patients and controls from northeastern Brazil. <i>Clinics</i> , 2011 , 66, 1485-8	2.3	10
50	Pharmacogenetics of Adverse Drug Reactions. 2006 , 65-89		1
49	The First Case of Abacavir Hypersensitivity Associated with the HLA-B*57:01-Positive Allele in Korea. <i>Infection and Chemotherapy</i> , 2012 , 44, 399	3.9	1
48	Cutaneous drug hypersensitivity: immunological and genetic perspective. <i>Indian Journal of Dermatology</i> , 2011 , 56, 137-44	0.9	3
47	Absence of human leukocyte antigen-B*57:01 amongst patients on antiretroviral therapy in Nigeria: Implications for use of abacavir. <i>Nigerian postgraduate medical journal, The</i> , 2019 , 26, 195-198	1.2	5
46	Pharmacogenetics as a tool to tailor antiretroviral therapy: A review. <i>World Journal of Virology</i> , 2015 , 4, 198-208	6.9	17
45	A Comprehensive Review of and Severe Cutaneous Adverse Drug Reactions: Implication for Clinical Pharmacogenomics and Precision Medicine. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	1
44	Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health. <i>Human Genetics</i> , 2021 , 1	6.3	0
43	Small Molecule/HLA Complexes Alter the Cellular Proteomic Content.		0
42	Human Genetics and HIV-1 Infection. 2004 , 207-221		
41	HIV und AIDS. 2008 , 849-887		

40 Cardiovascular Toxicities of Life-Saving Drugs: Antiviral Therapy. 313-332

39 Abacavir. **2011**, 201-212

38 Prevalence of human leukocyte antigen HLA-B*57:01 in HIV-infected subjects in the Czech Republic. *Central European Journal of Public Health*, **2011**, 19, 128-30

1.2 1

37 Pharmacogenomics in Developing Asian Countries. *Advances in Microbial Ecology*, **2012**, 183-214

36 Pharmacogenetics of Adverse Drug Reactions. 121-156

1

35 Pharmacogenetics and dermatology. **2012**, 1-14

34 Mechanisms of Adverse Drug Reactions. 463-487

33 The Role of Pharmacogenomics in Individualized Medicine. *Advances in Predictive, Preventive and Personalised Medicine*, **2015**, 93-112

0.4 0

32 Pharmacogenetics of Adverse Drug Reactions. *Advances in Predictive, Preventive and Personalised Medicine*, **2015**, 109-156

0.4

31 HLA and Drug Hypersensitivity. **2016**, 310-317

30 Concepts in Pharmacogenomics and Personalized Medicine. **2016**, 1-32

29 Adverse Medication Reactions. **2017**, 439-467

1

28 The Role of Conformational Dynamics in abacavir-Induced Hypersensitivity Syndrome.

27 Rapid Near Point-of-Care Assay for Genotype Associated with Severe Hypersensitivity Reaction to Abacavir. *AIDS Research and Human Retroviruses*, **2021**,

1.6 0

26 Pharmacogenomics of Anti-Infective Agents. **2020**, 123-136

25 Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection. *P and T*, **2015**, 40, 44-55

1.4 16

24 A Prospective Screening of HLA-B*57.01 Allelic Variant for Preventing the Hypersensitivity Reaction to Abacavir: Experience from the Laboratory of Molecular Biology of the Infectious Diseases Division at the University Hospital of Salerno. *Translational Medicine @ UniSa*, **2015**, 11, 55-8

0.5 1

23 Prevalence of HLA-B*5701 and Its Relationship with Abacavir Hypersensitivity Reaction in Iranian HIV-Infected Patients. *Tanaffos*, **2016**, 15, 48-52

0.5 4

22	Redrawing the map to novel DILI biomarkers in circulation: Where are we, where should we go, and how can we get there?. <i>Livers</i> , 2021 , 1, 286-293		3
21	Role of Pharmacogenomics in Reducing the Risk of Drug-Related Iatrogenesis. <i>Current Pharmacology Reports</i> , 2022 , 8, 79	5.5	0
20	Unravelling the Proteomics of HLA-B*57:01 Antigen Presenting Cells during Abacavir Medication.. <i>Journal of Personalized Medicine</i> , 2022 , 12,	3.6	1
19	The Immunogenetics of Cutaneous Drug Reactions.. <i>Advances in Experimental Medicine and Biology</i> , 2022 , 1367, 411-431	3.6	
18	Abacavir inhibits but does not cause self-reactivity to HLA-B*57:01-restricted EBV specific T cell receptors.. <i>Communications Biology</i> , 2022 , 5, 133	6.7	1
17	From pharmacogenetics to pharmaco-omics: Milestones and future directions.. <i>Human Genetics and Genomics Advances</i> , 2022 , 3, 100100	0.8	1
16	Data_Sheet_1.docx. 2019 ,		
15	DataSheet_1.docx. 2020 ,		
14	Triple Nucleoside Combination Zidovudine/Lamivudine/Abacavir versus Zidovudine/Lamivudine/Nelfinavir as First-Line Therapy in HIV-1-Infected Adults: A Randomized Trial. <i>Antiviral Therapy</i> , 2003 , 8, 163-171	1.6	33
13	A new era of antiretroviral drug toxicity. <i>Antiviral Therapy</i> , 2009 , 14, 165-179	1.6	25
12	Incidence of abacavir hypersensitivity reactions in EuroSIDA. <i>Antiviral Therapy</i> , 2008 , 13, 687-696	1.6	11
11	Refining Abacavir Hypersensitivity Diagnoses using a Structured Clinical Assessment and Genetic Testing in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2008 , 13, 1019-1028	1.6	21
10	HIV nucleoside reverse transcriptase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2022 , 114554	6.8	1
9	Functional and structural characteristics of HLA-B*13:01-mediated specific T cells reaction in dapsone-induced drug hypersensitivity. 2022 , 29,		0
8	TARC/CCL17 Expression Is Associated with CD8 ⁺ T Cell Recruitment in Abacavir-Induced Skin Hypersensitivity in HLA-Transgenic Mice. 2022 , 45, 1347-1353		0
7	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). 2022 , 133-141		0
6	Pharmacogenetics of Cutaneous Adverse Drug Reactions. 2022 , 3-34		0
5	Severe abacavir hypersensitivity reaction in a patient with human immunodeficiency virus infection: a case report. 2022 , 16,		0

- 4 HIV-Associated Immune Dysregulation in the Skin: A Crucible for Exaggerated Inflammation and Hypersensitivity. **2022**,
- 3 Delayed Drug Hypersensitivity Reactions: Molecular Recognition, Genetic Susceptibility, and Immune Mediators. **2023**, 11, 177
- 2 HLA-B*57:01/Carbamazepine-10,11-Epoxy Association Triggers Upregulation of the NF κ B and JAK/STAT Pathways. **2023**, 12, 676
- 1 Human leukocyte antigen HLA-B*57:01 status in HIV-1 patients developing hypersensitivity reactions in Benin: a pilot study.